United States - English - NLM (National Library of Medicine)

akorn - cetrorelix acetate (unii: w9y8l7gp4c) (cetrorelix - unii:oon1hfz4ba) - cetrorelix acetate for injection is indicated for the inhibition of premature lh surges in women undergoing controlled ovarian stimulation. cetrorelix acetate for injection is contraindicated under the following conditions: - hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. - known hypersensitivity to gnrh or any other gnrh analogs. - known or suspected pregnancy, and lactation (see precautions). - severe renal impairment

United States - English - NLM (National Library of Medicine)

emd serono, inc. - cetrorelix acetate (unii: w9y8l7gp4c) (cetrorelix - unii:oon1hfz4ba) - cetrorelix 0.25 mg in 1 ml - cetrotide® (cetrorelix acetate for injection) is indicated for the inhibition of premature lh surges in women undergoing controlled ovarian stimulation. cetrotide® (cetrorelix acetate for injection) is contraindicated under the following conditions: - hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. - known hypersensitivity to gnrh or any other gnrh analogs. - known or suspected pregnancy, and lactation (see precautions). - severe renal impairment

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals, inc. - cetrorelix acetate (unii: w9y8l7gp4c) (cetrorelix - unii:oon1hfz4ba) - cetrorelix acetate for injection is indicated for the inhibition of premature lh surges in women undergoing controlled ovarian stimulation. cetrorelix acetate for injection is contraindicated under the following conditions: - hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. - known hypersensitivity to gnrh or any other gnrh analogs. - known or suspected pregnancy, and lactation (see precautions). - severe renal impairment

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - cetrorelix (as cetrorelix acetate) - injection - 0.25 mg - cetrorelix (as cetrorelix acetate) 0.25 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cetrorelix acetate 0.26mg equivalent to 0.25 mg cetrorelix - injection with diluent - 250 mcg - active: cetrorelix acetate 0.26mg equivalent to 0.25 mg cetrorelix excipient: mannitol water for injection - prevention of premature luteinization and ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cetrorelix acetate 3.12mg equivalent to 3.00 mg cetrorelix - injection with diluent - 3 mg - active: cetrorelix acetate 3.12mg equivalent to 3.00 mg cetrorelix excipient: mannitol water for injection - prevention of premature luteinization and ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques.

Canada - English - Health Canada

emd serono, a division of emd inc., canada - cetrorelix (cetrorelix acetate) - powder for solution - 3mg - cetrorelix (cetrorelix acetate) 3mg - gonadotropin-releasing hormone antagonists

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sun pharmaceutical industries europe b.v. - cetrorelix acetate - eq. cetrorelix 0,25 mg/ml - solution for injection in pre-filled syringe - 0,25 mg - cetrorelix acetate - cetrorelix

Canada - English - Health Canada

emd serono, a division of emd inc., canada - cetrorelix (cetrorelix acetate) - powder for solution - 0.25mg - cetrorelix (cetrorelix acetate) 0.25mg - gonadotropin-releasing hormone antagonists

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 5 mg - norethindrone acetate tablets, usp is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. norethindrone acetate tablets, usp are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. - known or suspected pregnancy. there is no indication for norethindrone acetate, usp in pregnancy. (see precautions .) - undiagnosed vaginal bleeding - known, suspected or history of cancer of the breast - active deep vein thrombosis, pulmonary embolism or history of these conditions - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) - impaired liver function or liver disease - as a diagnostic test for pregnancy - hypersensitivity to any of the drug components